DSNKY – daiichi sankyo s/adr (US:NASDAQ)

News

Is Daiichi Sankyo Now an Opportunity After a 26% Share Price Slide? [Yahoo! Finance]
Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute between Daiichi Sankyo and Seagen
Allegro and American Regent sign exclusive licensing deal for SynoglideTM, a novel osteoarthritis treatment in animal health, valued at up to $35 million [Yahoo! Finance]
Allegro and American Regent sign exclusive licensing deal for SynoglideTM, a novel osteoarthritis treatment in animal health, valued at up to $35 million
Daiichi Sankyo (OTCMKTS:DSNKY) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com